Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
BioCardia, Inc. (BCDA) Insider Trading Activity
Healthcare • Biotechnology • 16 employees
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Total Value
$208,041.92
Total Shares
83,637
Average Trade Value
$13,002.62
Most Active Insider
Altman Peter
Total Activity: $184,166
Largest Single Transaction
$117,263
by Altman Peter on Oct 11, 2024
30-Day Activity
1 Transaction
Volume: 15,536 shares
Value: $35,733
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Mar 4, 2025 | 15,536 | $35,733 | 56,138 (+27.7%) | Purchase | |
|
Director
|
Mar 3, 2025 | 22,753 | $52,332 | 40,602 (+56.0%) | Purchase | |
|
President and CEO
Director, Officer
|
Mar 3, 2025 | 500 | $1,055 | 108,420 (+0.5%) | Purchase | |
|
President and CEO
Director, Officer
|
Feb 7, 2025 | 600 | $1,488 | 107,920 (+0.6%) | Purchase | |
|
President and CEO
Director, Officer
|
Jan 30, 2025 | 239 | $569 | 107,320 (+0.2%) | Purchase | |
|
President and CEO
Director, Officer
|
Jan 29, 2025 | 500 | $1,200 | 107,081 (+0.5%) | Purchase | |
|
President and CEO
Director, Officer
|
Dec 23, 2024 | 1,000 | $2,060 | 106,581 (+0.9%) | Purchase | |
|
Senior Vice President, Devices
Officer
|
Dec 20, 2024 | 3,257 | $6,514 | 8,968 (-36.3%) | Sale | |
|
President and CEO
Director, Officer
|
Dec 5, 2024 | 250 | $555 | 105,581 (+0.2%) | Purchase | |
|
President and CEO
Director, Officer
|
Nov 15, 2024 | 1,350 | $2,525 | 105,331 (+1.3%) | Purchase | |
|
Chief Financial Officer
Officer
|
Oct 11, 2024 | 24,193 | $64,111 | 41,573 (+58.2%) | Grant | |
|
Chief Financial Officer
Officer
|
Oct 11, 2024 | 11,565 | $30,647 | 30,008 (-38.5%) | Payment of Exercise Price | |
|
Senior Vice President, Devices
Officer
|
Oct 11, 2024 | 15,808 | $41,891 | 19,065 (+82.9%) | Grant | |
|
President and CEO
Director, Officer
|
Oct 11, 2024 | 21,680 | $57,452 | 103,981 (-20.8%) | Payment of Exercise Price | |
|
Senior Vice President, Devices
Officer
|
Oct 11, 2024 | 6,840 | $18,126 | 12,225 (-56.0%) | Payment of Exercise Price | |
|
President and CEO
Director, Officer
|
Oct 11, 2024 | 44,250 | $117,263 | 125,661 (+35.2%) | Grant |